Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Short term Debt: 2019-2022

Historic Short term Debt for Pharming Group N.V (PHAR) over the last 2 years, with Sep 2022 value amounting to $143,000.

  • Pharming Group N.V's Short term Debt fell 62.95% to $143,000 in Q3 2022 from the same period last year, while for Sep 2022 it was $143,000, marking a year-over-year decrease of 62.95%. This contributed to the annual value of $171,593 for FY2021, which is 99.31% down from last year.
  • Latest data reveals that Pharming Group N.V reported Short term Debt of $143,000 as of Q3 2022, which was down 5.92% from $152,000 recorded in Q2 2022.
  • In the past 5 years, Pharming Group N.V's Short term Debt registered a high of $25.0 million during Q4 2020, and its lowest value of $143,000 during Q3 2022.
  • For the 3-year period, Pharming Group N.V's Short term Debt averaged around $3.3 million, with its median value being $177,438 (2021).
  • Per our database at Business Quant, Pharming Group N.V's Short term Debt grew by 25.00% in 2020 and then tumbled by 99.34% in 2021.
  • Pharming Group N.V's Short term Debt (Quarterly) stood at $20.0 million in 2019, then climbed by 25.00% to $25.0 million in 2020, then slumped by 99.34% to $165,876 in 2021, then crashed by 62.95% to $143,000 in 2022.
  • Its Short term Debt was $143,000 in Q3 2022, compared to $152,000 in Q2 2022 and $162,000 in Q1 2022.